Trial Profile
A Double-Blind, Randomized, Parallel Group, Proof of Concept Study Comparing FX006 to Kenalog-40 in Active Military and Medically Retired Patients With Post-Traumatic Osteoarthritis of the Knee
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Triamcinolone (Primary)
- Indications Musculoskeletal pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Flexion Therapeutics
- 06 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 16 May 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2016.
- 16 May 2016 Status changed from recruiting to active, no longer recruiting.